These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27548624)

  • 1. Barriers experienced by patients with multiple sclerosis in seeking care for lower urinary tract symptoms.
    Brucker BM; Nitti VW; Kalra S; Herbert J; Sadiq A; Utomo P; Aponte MM
    Neurourol Urodyn; 2017 Apr; 36(4):1208-1213. PubMed ID: 27548624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Turkish version of the eight-item actionable bladder symptom screening tool in multiple sclerosis.
    Polat Dunya C; Tulek Z; Vızvız GY; Gündüz T; Panicker JN; Kürtüncü M; Eraksoy M
    Neurourol Urodyn; 2020 Jan; 39(1):243-252. PubMed ID: 31588627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplified scoring of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: a comparative analysis of test performance at different cut-off points.
    Jongen PJ; Blok BF; Heesakkers JP; Heerings M; Lemmens WA; Donders R
    BMC Urol; 2015 Oct; 15():106. PubMed ID: 26498107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.
    De Ridder D; Van Der Aa F; Debruyne J; D'hooghe MB; Dubois B; Guillaume D; Heerings M; Ilsbroukx S; Medaer R; Nagels G; Seeldrayers P; Van Landegem W; Willekens B; Zicot AF
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2033-40. PubMed ID: 23880016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder.
    Cardozo L; Staskin D; Currie B; Wiklund I; Globe D; Signori M; Dmochowski R; MacDiarmid S; Nitti VW; Noblett K
    Int Urogynecol J; 2014 Dec; 25(12):1655-63. PubMed ID: 24859795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool.
    Bates D; Burks J; Globe D; Signori M; Hudgens S; Denys P; Macdiarmid S; Nitti V; Odderson I; Ross AP; Chancellor M
    BMC Neurol; 2013 Jul; 13():78. PubMed ID: 23837535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive bladder symptoms in patients with multiple sclerosis: Frequency, severity, diagnosis and treatment.
    Akkoç Y; Ersöz M; Yüceyar N; Tunç H; Köklü K; Yoldaş TK; Dönmez Ü; Uzunköprü C; Alemdaroğlu E; Bilen Ş; Emre U; Özdolap Ş; Tuncay E; Yücesan C; Gök H; Ercan MB; Uygunol K; Koçer B; Zinnuroğlu M;
    J Spinal Cord Med; 2016; 39(2):229-33. PubMed ID: 25936385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
    Medina-Polo J; Adot JM; Allué M; Arlandis S; Blasco P; Casanova B; Matías-Guiu J; Madurga B; Meza-Murillo ER; Müller-Arteaga C; Rodríguez-Acevedo B; Vara J; Zubiaur MC; López-Fando L
    Neurourol Urodyn; 2020 Feb; 39(2):762-770. PubMed ID: 31943361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis].
    Bazhenov IV; Filippova ES; Bazarnyi VV; Sazonov SV; Volkova LI; Zaitseva LN
    Urologiia; 2018 Jul; (3):44-48. PubMed ID: 30035417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.
    Tubaro A; Puccini F; De Nunzio C; Digesu GA; Elneil S; Gobbi C; Khullar V
    Curr Urol Rep; 2012 Oct; 13(5):335-42. PubMed ID: 22886612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series.
    Engeler DS; Meyer D; Abt D; Müller S; Schmid HP
    BMC Urol; 2015 Oct; 15():105. PubMed ID: 26498275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a Dutch version of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: an observational web-based study.
    Jongen PJ; Blok BF; Heesakkers JP; Heerings M; Lemmens WA; Donders R
    Health Qual Life Outcomes; 2015 Oct; 13():175. PubMed ID: 26518712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we predict detrusor overactivity in women with lower urinary tract symptoms? The King's Detrusor Overactivity Score (KiDOS).
    Giarenis I; Musonda P; Mastoroudes H; Robinson D; Cardozo L
    Eur J Obstet Gynecol Reprod Biol; 2016 Oct; 205():127-32. PubMed ID: 27592416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluid Intake and Urinary Symptoms in Patients with Multiple Sclerosis.
    Tam J; Gross MD; Cheung A; Melville PM; Kim JM; Weissbart SJ
    J Urol; 2020 Dec; 204(6):1284-1289. PubMed ID: 32924823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transcultural validation in Spanish of the Actionable Bladder Symptoms Screening Tool].
    Munoz-Ruiz T; Fernandez-Sanchez VE; Reyes-Garrido V; Martinez-Tomas C; Urbaneja-Romero P; Gallardo-Tur A; Guerrero-Fernandez M; Leon-Martin A; Fernandez O
    Rev Neurol; 2017 May; 64(9):401-406. PubMed ID: 28444682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of sacral nerve modulation in a series of multiple sclerosis patients with bladder dysfunction.
    Andretta E; Simeone C; Ostardo E; Pastorello M; Zuliani C
    J Neurol Sci; 2014 Dec; 347(1-2):257-61. PubMed ID: 25454644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
    Haab F
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuro-urological diagnostics and treatment of non-traumatic/degenerative neurogenic lower urinary tract dysfunction exemplified by multiple sclerosis].
    Kurze I; Jaekel AK
    Aktuelle Urol; 2024 Aug; 55(4):315-325. PubMed ID: 38653466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study.
    Zecca C; Digesu GA; Robshaw P; Singh A; Elneil S; Gobbi C
    J Urol; 2014 Mar; 191(3):697-702. PubMed ID: 24076308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients.
    Burks J; Chancellor M; Bates D; Denys P; Macdiarmid S; Nitti V; Globe D; Signori M; Hudgens S; Odderson I; Panicker J; Ross AP
    Int J MS Care; 2013; 15(4):182-92. PubMed ID: 24453782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.